Invivyd Inc., based in Waltham, Massachusetts, has announced an underwritten public offering of its common stock. The company plans to grant underwriters a 30-day option to purchase an additional 15% of the shares sold, at the public offering price, minus underwriting discounts and commissions. Cantor is acting as the sole book-running manager for this offering. Invivyd intends to use the net proceeds from the offering to support trial protocol development, advance the VYD2311 clinical program, conduct research and development for its pipeline programs, such as RSV and measles, and further initiatives related to monoclonal antibody therapy for Long COVID and COVID-19 Post-Vaccination Syndrome. The offering is subject to market conditions, and its completion or final terms have not been guaranteed.